Analysts Set Gossamer Bio, Inc. (NASDAQ:GOSS) Target Price at $3.20

Shares of Gossamer Bio, Inc. (NASDAQ:GOSS) have been assigned a consensus recommendation of “Hold” from the nine ratings firms that are covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $3.20.

GOSS has been the subject of a number of recent analyst reports. Weiss Ratings raised Gossamer Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 27th. HC Wainwright reiterated a “buy” rating on shares of Gossamer Bio in a research note on Thursday, August 27th. Finally, Leerink Partners upgraded shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $1.00 price target for the company in a research note on Tuesday, July 28th.

Institutional Investors Weigh In On Gossamer Bio

Large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc bought a new position in shares of Gossamer Bio during the 2nd quarter valued at $26,000. Banco BTG Pactual S.A. purchased a new position in shares of Gossamer Bio in the 2nd quarter worth $27,000. Soltis Investment Advisors LLC bought a new stake in shares of Gossamer Bio in the fourth quarter worth $31,000. MMA Asset Management LLC bought a new stake in shares of Gossamer Bio in the fourth quarter worth $31,000. Finally, Beacon Pointe Advisors LLC purchased a new stake in Gossamer Bio during the fourth quarter valued at $34,000. Institutional investors own 81.23% of the company’s stock.

Gossamer Bio Trading Down 1.5%

Gossamer Bio stock opened at $0.17 on Wednesday. Gossamer Bio has a 12 month low of $0.11 and a 12 month high of $3.87. The stock has a fifty day simple moving average of $0.17 and a two-hundred day simple moving average of $0.37. The firm has a market cap of $39.29 million, a price-to-earnings ratio of -0.24 and a beta of 2.00.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.04. The business had revenue of $9.24 million for the quarter, compared to the consensus estimate of $3.63 million. On average, equities research analysts forecast that Gossamer Bio will post -0.41 EPS for the current fiscal year.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.